Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics granted non-qualified stock options to purchase 200,000 shares to a new employee under its 2025 Inducement Plan. The options carry a $0.86 exercise price (matching the October 13, 2026 close), a 10-year term, and four-year vesting.
Key figures
- Vesting years
- 4
- Exercise price
- 0.86
- Options granted
- 200000
- Option term years
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.